USPC-ARK-3 (Q54991972)

From Wikidata

Jump to navigation Jump to search

cell line

USPC ARK-3
USPC-ARK3
ARK3

Language	Label	Description	Also known as
English	USPC-ARK-3	cell line	USPC ARK-3 USPC-ARK3 ARK3

Statements

1 reference

Cellosaurus release 44

31 January 2023

cancer cell line

1 reference

Cellosaurus release 44

31 January 2023

described by source

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

1 reference

Cellosaurus release 44

31 January 2023

Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody

1 reference

Cellosaurus release 44

31 January 2023

Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).

1 reference

Cellosaurus release 44

31 January 2023

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.

1 reference

Cellosaurus release 44

31 January 2023

established from medical condition

uterine corpus serous adenocarcinoma

1 reference

Cellosaurus release 26

14 June 2018

derived from organism type

1 reference

Cellosaurus release 44

31 January 2023

Identifiers

1 reference

Cellosaurus release 44

31 January 2023

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54991972&oldid=1861782321"